<DOC>
	<DOCNO>NCT02419001</DOCNO>
	<brief_summary>A Phase 1b/2a , Randomized , Multi-Center , Open-Label , Fixed-Sequence Study Evaluate Effect Oral SYN-004 Pharmacokinetics Intravenous Ceftriaxone Healthy Adult Subjects Functioning Ileostomy .</brief_summary>
	<brief_title>A Study Evaluate Effect SYN-004 PK IV Ceftriaxone Adults With Functioning Ileostomy</brief_title>
	<detailed_description>This Phase 1b/2a , randomize , multi-center , open-label study . Twenty otherwise healthy subject age 18 80 year , inclusive , function ileostomy plan enrol . In first treatment period ( Period 1 ) subject receive IV infusion 1 g ceftriaxone . Subjects 3 - 7 day washout period Period 1 Period 2 . In second treatment period ( Period 2 ) subject receive IV infusion 1 g ceftriaxone 2 oral dos either 75 150 mg SYN-004 , accord randomization schedule , administer 30 minute 5.5 hour start ceftriaxone infusion .</detailed_description>
	<mesh_term>Ceftriaxone</mesh_term>
	<criteria>1 . The subject function ileostomy place &gt; 3 month . 2 . Male female age 18 70 year , inclusive . 3 . Other function ileostomy , subject free clinically significant illnesses disease . 1 . Subjects active hepatic , small intestine , biliary tract disease . 2 . Subjects active ulcerative colitis , Crohn 's disease , inflammatory bowel disease . 3 . Subjects know malignancy require treatment &lt; 6 month prior study screen . 4 . Subjects , opinion investigator , significant concurrent medical illness . 5 . Subjects currently take concomitant medication may interfere study evaluation . 6 . Subjects receive investigational drug within 30 day within time period consistent washout period 5 halflives , whichever longer , first dose ceftriaxone . 7 . Subjects know history allergy cephalosporin , penicillin Î²lactam antibiotic . 8 . Subjects know active malabsorption syndrome ( ) , judgment investigator , could compromise objective study . 9 . Subjects used oral , intramuscular , IV antimicrobial medication last 3 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>